Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
STDM | Paris | EUR | Real-time | |
DIMp | BATS Europe | EUR | Delayed | |
56S1 | Frankfurt | EUR | Delayed | |
DIM | Vienna | EUR | Real-time |
Sartorius Stedim Biotech S.A. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was EUR 666.9 million compared to EUR 878.4 million a year ago. Net income was EUR 25.7 million compared to EUR 200.6 million a year ago. Basic earnings per share from continuing operations was EUR 0.28 compared to EUR 2.18 a year ago. Diluted earnings per share from continuing operations was EUR 0.28 compared to EUR 2.18 a year ago.For the nine months, sales was EUR 2,068.7 million compared to EUR 2,602.7 million a year ago. Net income was EUR 269.9 million compared to EUR 685.6 million a year ago. Basic earnings per share from continuing operations was EUR 2.93 compared to EUR 7.44 a year ago. Diluted earnings per share from continuing operations was EUR 2.93 compared to EUR 7.44 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 666.9 | 675.7 | 726.1 | |
Gross Profit | 280.9 | 324.9 | 374.5 | |
Operating Income | 125.1 | 76.8 | 112.9 | 153.7 |
Net Income | 25.7 | 133.1 | 111.1 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 7958.9 | 5187.2 | 5096.7 | |
Total Liabilities | 5330.2 | 2584.5 | 2642.4 | |
Total Equity | 2628.7 | 2602.7 | 2454.3 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 98.4 | 146.4 | 165.6 | |
Cash From Investing Activities | -2332.9 | -168.8 | -115.8 | |
Cash From Financing Activities | 2224.4 | 39.1 | -63.5 | |
Net Change in Cash | -10.8 | 16.1 | -13.1 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review